Headlines about Viveve Medical (NASDAQ:VIVE) have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viveve Medical earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.4223083446901 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
A number of equities research analysts have weighed in on VIVE shares. Maxim Group restated a “buy” rating and issued a $11.00 target price on shares of Viveve Medical in a research report on Friday, August 11th. ValuEngine cut Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $11.00 price target on shares of Viveve Medical in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $10.50.
Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.21). Viveve Medical had a negative net margin of 266.93% and a negative return on equity of 244.96%. The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $3.24 million. During the same period in the previous year, the business posted ($0.66) earnings per share. Viveve Medical’s revenue was up 97.4% compared to the same quarter last year.
In other Viveve Medical news, CFO Scott Durbin acquired 5,000 shares of Viveve Medical stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $5.25 per share, with a total value of $26,250.00. Following the completion of the purchase, the chief financial officer now owns 11,568 shares in the company, valued at $60,732. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 35.10% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Viveve Medical (VIVE) Stock Price” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-viveve-medical-vive-stock-price.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.